Perceptive Advisors
Perceptive Advisors reported 101 stocks worth $6.4B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PRAX (10.6%), SYRE (6.0%) and CELC (5.2%). Compared with Q1 2026, the fund opened new positions in ASND, KARD and AVLN, added to SYRE, CELC and RYTM, trimmed ROIV, TVTX and EWTX and sold out of ASND, DRUG and BLTE.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  PRAX Praxis Precision Medicines I | $682M | 10.6% | 2M | No change | 8 of 8 | |
| 2 |  SYRE Spyre Therapeutics Inc | $383M | 6.0% | 4.3M | +536K (+14%) | 8 of 8 | |
| 3 |  CELC Celcuity Inc | $334M | 5.2% | 3.2M | +70K (+2%) | 8 of 8 | |
| 4 |  ASND Ascendis Pharma A/s | $310M | 4.8% | 1.2M | New position | 1 of 8 | |
| 5 |  RYTM Rhythm Pharmaceuticals Inc | $287M | 4.5% | 2.6M | +213K (+9%) | 8 of 8 | |
| 6 |  ROIV Roivant Sciences Ltd | $286M | 4.5% | 8.1M | −200K (−2%) | 6 of 8 | |
| 7 |  RLAY Relay Therapeutics Inc | $264M | 4.1% | 14.1M | +4.4M (+45%) | 3 of 8 | |
| 8 |  TVTX Travere Therapeutics Inc | $213M | 3.3% | 3.8M | −390K (−9%) | 5 of 8 | |
| 9 |  KARD Kardigan Inc | $196M | 3.0% | 8.2M | New position | 1 of 8 | |
| 10 | NUVALENT INC | $195M | 3.0% | 1.6M | No change | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
ASND Ascendis Pharma A/s | $350M | 1.5M |
CENTESSA PHARMACEUTICALS PLC | $209M | 5.3M |
ENGENE HOLDINGS INC | $39.7M | 5.8M |
DAY ONE BIOPHARMACEUTICALS I | $37.6M | 1.8M |
 DRUG Bright Minds Biosciences Inc | $27.5M | 378K |
🔒 Free account: see all 13.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 MRNA Moderna Inc | Put | $70M | 1M | 0 |
 XBI Spdr Series Trust | Put | $47.5M | 300K | +300,000 |
 EYPT Eyepoint Pharmaceuticals Inc | Put | $28.6M | 2M | +2,000,000 |
 CAPR Capricor Therapeutics Inc | Call | $24.1M | 1M | +1,000,000 |
 SLS Sellas Life Sciences Group I | Put | $22.1M | 1.5M | +1,500,000 |
🔒 Free account: see all 7.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Perceptive Advisors 13F FAQ
What does Perceptive Advisors own?
Perceptive Advisors reported 101 stocks worth $6.4B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PRAX (10.6%), SYRE (6.0%) and CELC (5.2%). The table above lists every position in the filing (the top 10 without an account).
What did Perceptive Advisors buy and sell in Q2 2026?
Compared with Q1 2026: 23 new positions, 29 added to, 26 trimmed and 13 sold out. New positions include ASND, KARD and AVLN. It sold all of ASND, DRUG and BLTE.
When will Perceptive Advisors file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Perceptive Advisors's portfolio worth?
The Q2 2026 filing reports $6.4B in US stocks ($6.6B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.